rabeprazole + vismodegib

This is a **combination of rabeprazole and vismodegib administered concomitantly**. Rabeprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by irreversibly inhibiting the gastric H+/K+-ATPase in parietal cells, thereby raising gastric pH. Vismodegib is a small molecule inhibitor targeting the Hedgehog signaling pathway by antagonizing the transmembrane receptor Smoothened (SMO), used primarily for the treatment of basal cell carcinoma. This combination is not a fixed-dose commercial product but refers to the co-administration of both agents, which is sometimes clinically relevant since vismodegib has pH-dependent solubility and is often used in oncology patients who may also require acid suppression therapy. Clinical drug-drug interaction studies have demonstrated that co-administration leads to a moderate reduction in vismodegib exposure, but this interaction is not considered clinically significant[1][2][3].